Cantuzumab ravtansine

Drug Profile

Cantuzumab ravtansine

Alternative Names: C-242 DM4; C242 DM4 immunoconjugate; C242 maytansinoid-4 conjugate; huC242-DM4; IMGN-242; Maytasinoid DM4-conjugated humanised monoclonal antibody huC242; Monoclonal antibody C-242 DM4 conjugate

Latest Information Update: 15 Jun 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImmunoGen
  • Class Antineoplastics; Immunoconjugates; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gastric cancer; Solid tumours

Most Recent Events

  • 12 Jun 2009 Discontinued - Phase-I for Solid tumours in USA (IV)
  • 12 Jun 2009 Discontinued - Phase-II for Gastric cancer in USA (IV)
  • 25 Oct 2007 Data presented at the 19th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2007) added to the adverse events and Cancer therapeutic trials and pharmacodynamics sections ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top